Titre :

Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT.

Auteur(s) :

Pagliuca, Simona [Auteur]
Université de Lorraine [UL]
Schmid, Christoph [Auteur]
Santoro, Nicole [Auteur]
Simonetta, Frederico [Auteur]
Battipaglia, Giorgia [Auteur]
Guillaume, Thierry [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Greco, Raffaella [Auteur]
Onida, Francesco [Auteur]
Sánchez-Ortega, Isabel [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Kuball, Jurgen [Auteur]
Hazenberg, Mette D. [Auteur]
Ruggeri, Annalisa [Auteur]

Titre de la revue :

The Lancet Haematology

Nom court de la revue :

Lancet Haematol

Numéro :

11

Pagination :

e448-e458

Date de publication :

2024-06

ISSN :

2352-3026

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Since the early description of three patients with relapsed leukaemia after allogeneic haematopoietic cell transplantation (HCT) who obtained complete remission after donor lymphocyte infusions (DLIs), the added value of ...
Lire la suite >Since the early description of three patients with relapsed leukaemia after allogeneic haematopoietic cell transplantation (HCT) who obtained complete remission after donor lymphocyte infusions (DLIs), the added value of this procedure to induce or maintain graft-versus-leukaemia immunity has been undisputed. For more than 30 years, DLIs have become common practice as prophylactic, pre-emptive, or therapeutic immunotherapy. However, as with many aspects of allogeneic HCT, centres have developed their own routines and practices, and many questions related to the optimal applications and toxicity, or to the immunobiology of DLI induced tumour-immunity, remain. As a part of the Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation effort, a panel of experts with clinical and translational knowledge in transplantation immunology and cellular therapy met during a 2-day workshop in September, 2023, in Lille, France, and developed a set of consensus-based recommendations for the application of unmanipulated DLI after allogeneic HCT for haematological malignancies. Given the absence of prospective data in the majority of publications, these recommendations are mostly based on retrospective studies and expert consensus.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-06-25T21:09:12Z
2024-08-20T13:38:52Z